Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients

Journal of Autoimmunity

Volumn 27, Issue 4, 2006, Pages 211-217

  Kiss, Emese ^a   Soltesz, Pal ^a   Der, Henrietta ^a   Kocsis, Zsolt ^a   Tarr, Tunde ^a   Bhattoa, Harjit ^a   Shoenfeld, Yehuda ^b   Szegedi, Gyula ^a,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SHEBA MEDICAL CENTER   (Israel)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Atherosclerosis; Endothelial dysfunction; FMD; SLE

Indexed keywords

ARYLDIALKYLPHOSPHATASE; GLYCERYL TRINITRATE; LIPID; LOW DENSITY LIPOPROTEIN; NITRATE; PHOSPHOLIPID ANTIBODY;

ADULT; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; B SCAN; BLOOD FLOW VELOCITY; BLOOD VESSEL DIAMETER; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; COMMON CAROTID ARTERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DIAGNOSTIC PROCEDURE; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPEREMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEADY STATE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

ADULT; ATHEROSCLEROSIS; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; VASODILATION;

EID: 33846810195     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2006.09.008     Document Type: Review

References (38)

1. Kiss E., Regeczy N., and Szegedi G. Systemic lupus erythematosus survival in Hungary. Results from a single centre. Clin Exp Rheumatol 17 (1999) 171-177
2. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 78 (1999) 167-175
3. Petri M., Perez-Gutthann S., Spence D., and Hochberg M.C. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93 (1992) 513-519
4. Esdaile J.M., Abrahamowicz M., Grodzicky T., Li Y., Panaritis C., du Berger R., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44 (2001) 2331-2337
5. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger Jr. T.A., Jansen-McWilliams L., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145 (1997) 408-415
6. Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 257 (2005) 485-495
7. Frostegard J., Ulfgren A.K., Nyberg P., Hedin U., Swedenborg J., Andersson U., et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145 (1999) 33-43
8. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481-3488
9. Shoenfeld Y., Sherer Y., and Harats D. Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 22 (2001) 293-295
10. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
11. Zhou X., Nicoletti A., Elhage R., and Hansson G.K. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102 (2000) 2919-2922
12. George J., Harats D., Gilburd B., Afek A., Shaish A., Kopolovic J., et al. Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 102 (2000) 1822-1827
13. Sorensen K.E., Celermajer D.S., Spiegelhalter D.J., Georgakopoulos D., Robinson J., Thomas O., et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 74 (1995) 247-253
14. Joannides R., Haefeli W.E., Linder L., Richard V., Bakkali E.H., Thuillez C., et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91 (1995) 1314-1319
15. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 8 (2001) 756-762
16. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. International Brachial Artery Reactivity Task Force: guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2002) 257-265
17. Kiss E., Seres I., Zsolt K., Tarr T., Csipo I., Szegedi G., et al. Analysis of paraoxonase activity and lipid profile in lupus patients. Orv Hetil 146 (2005) 2395-2402
18. Pasqualini L., Cortese C., Marchesi S., Siepi D., Pirro M., Vaudo G., et al. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 183 (2005) 349-354
19. Ruiz J., Blanche H., James R.W., Garin M.C., Vaisse C., Charpentier G., et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346 (1995) 869-872
20. Durrington P.N., Mackness B., and Mackness M.I. The hunt for nutritional and pharmacological modulators of paraoxonase. Arterioscler Thromb Vasc Biol 22 (2002) 1248-1250
21. Navab M., Hama-Levy S., Van Lenten B.J., Fonarow G.C., Cardinez C.J., Castellani L.W., et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 99 (1997) 2005-2019
22. Delgado Alves J., Ames P.R., Donohue S., Stanyer L., Nourooz-Zadeh J., Ravirajan C., et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46 (2002) 2686-2694
23. Frostegard J. Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun Rev 1 (2002) 233-237
24. Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M.M., Ronda N., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112 (2005) 3337-3347
25. Kanters S.D., Algra A., van Leeuwen M.S., and Banga J.D. Reproducibility of in vivo carotid intima-media thickness measurements: a review. Stroke 28 (1997) 665-6671
26. Mitsias P., and Levine S.R. Large cerebral vessel occlusive disease in systemic lupus erythematosus. Neurology 44 (1994) 385-393
27. Wolak T., Todosoui E., Szendro G., Bolotin A., Jonathan B.S., Flusser D., et al. Duplex study of the carotid and femoral arteries of patients with systemic lupus erythematosus: a controlled study. J Rheumatol 31 (2004) 909-914
28. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 (2003) 2399-2406
29. Hochberg M. Updating American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40 (1997) 1725-1734
30. Moens A.L., Goovaerts I., Claeys M.J., and Vrints C.J. Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool?. Chest 127 (2005) 2254-2263
31. Exner T., Triplett D.A., Taberner D., and Machin S.J. Guidelines for the testing and revised criteria for lupus anticoagulant. Thromb Haemost 65 (1991) 320-322
32. Galindo M., Chung L., Crockett S.D., and Chakravrty E.F. Coronary artery disease in patients with systemic lupus erythematosus. Nat Clin Practice Rheumatol 1 (2005) 55-59
33. Nikpour M., Urowitz M.B., and Gladman D.D. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 31 (2005) 329-354
34. Jimenez S., Garcia-Criado M.A., Tassies D., Reverter J.C., Cervera R., Gilabert M.R., et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 6 (2005) 756-761
35. Lima D.S., Sato E.I., Lima V.C., Miranda Jr. F., and Hatta F.H. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 29 (2002) 292-297
36. Karadag O., Calguneri M., Atalar E., Yavuz B., Akdogan A., Kalyoncu U., et al. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clin Rheumatol Aug 15 (2006) [Epub ahead of print]
37. Doria A., Shoenfeld Y., Wu R., Gambari P.F., Puato M., Ghirardello A., et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62 (2003) 1071-1077
38. El-Magadmi M., Bodill H., Ahmad Y., Durrington P.N., Mackness M., Walker M., et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 110 (2004) 399-404